Literature DB >> 8113411

Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep.

W M Abraham1, M W Sielczak, A Ahmed, A Cortes, I T Lauredo, J Kim, B Pepinsky, C D Benjamin, D R Leone, R R Lobb.   

Abstract

Eosinophils and T lymphocytes are thought to be involved in allergic airway inflammation. Both cells express the alpha 4 beta 1-integrin, very late antigen-4 (VLA-4, CD49d/CD29); alpha 4-integrins can promote cellular adhesion and activation. Therefore, we examined the in vivo effects of a blocking anti-alpha 4 monoclonal antibody, HP 1/2, on antigen-induced early and late bronchial responses, airway hyperresponsiveness, inflammatory cell influx, and peripheral leukocyte counts in allergic sheep. Sheep blood lymphocytes, monocytes, and eosinophils expressed alpha 4 and bound HP 1/2. In control sheep, Ascaris antigen challenge produced early and late increases in specific lung resistance of 380 +/- 42% and 175 +/- 16% over baseline immediately and 7 h after challenge, respectively, as well as airway hyperresponsiveness continuing for 14 d after antigen challenge. Treatment with HP 1/2 (1 mg/kg, i.v.) 30 min before antigen challenge did not affect the early increase in specific lung resistance but inhibited the late-phase increase at 5-8 h by 75% (P < 0.05) and inhibited the post-antigen-induced airway hyperresponsiveness at 1, 2, 7, and 14 d (P < 0.05, for each time). Intravenous HP 1/2 given 2 h after antigen challenge likewise blocked late-phase airway changes and postchallenge airway hyperresponsiveness. Airway administration of HP 1/2 (16-mg dose) was also effective in blocking these antigen-induced changes. Response to HP 1/2 was specific since an isotypic monoclonal antibody, 1E6, was ineffective by intravenous and aerosol administration. Inhibition of leukocyte recruitment did not totally account for the activity of anti-alpha 4 antibody since HP 1/2 neither diminished the eosinopenia or lymphopenia that followed antigen challenge nor consistently altered the composition of leukocytes recovered by bronchoalveolar lavage. Because airway administration of HP 1/2 was also active, HP 1/2 may have inhibited cell activation. Reduction of platelet-activating factor-induced eosinophil peroxidase release from HP 1/2-treated eosinophils supports such a mechanism. These findings indicate a role for alpha 4-integrins in processes that lead to airway late phase responses and persisting airway hyperresponsiveness after antigen challenge.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113411      PMCID: PMC293928          DOI: 10.1172/JCI117032

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma.

Authors:  A M Bentley; P Maestrelli; M Saetta; L M Fabbri; D S Robinson; B L Bradley; P K Jeffery; S R Durham; A B Kay
Journal:  J Allergy Clin Immunol       Date:  1992-04       Impact factor: 10.793

2.  Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation.

Authors:  L C Burkly; A Jakubowski; B M Newman; M D Rosa; G Chi-Rosso; R R Lobb
Journal:  Eur J Immunol       Date:  1991-11       Impact factor: 5.532

3.  VLA-3: a novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization.

Authors:  F Sánchez-Madrid; M O De Landázuri; G Morago; M Cebrián; A Acevedo; C Bernabeu
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

4.  A bradykinin-antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep.

Authors:  M Solèr; M Sielczak; W M Abraham
Journal:  Pulm Pharmacol       Date:  1990

5.  Epithelial augmentation of trachealis contraction caused by major basic protein of eosinophils.

Authors:  J D Brofman; S R White; J S Blake; N M Munoz; G J Gleich; A R Leff
Journal:  J Appl Physiol (1985)       Date:  1989-04

6.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro.

Authors:  S Motojima; E Frigas; D A Loegering; G J Gleich
Journal:  Am Rev Respir Dis       Date:  1989-03

7.  A PAF antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep.

Authors:  M Solèr; M W Sielczak; W M Abraham
Journal:  J Appl Physiol (1985)       Date:  1989-07

8.  Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity.

Authors:  C Walker; M K Kaegi; P Braun; K Blaser
Journal:  J Allergy Clin Immunol       Date:  1991-12       Impact factor: 10.793

9.  Cloning and expression of cDNAs for the alpha subunit of the murine lymphocyte-Peyer's patch adhesion molecule.

Authors:  H Neuhaus; M C Hu; M E Hemler; Y Takada; B Holzmann; I L Weissman
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

10.  Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein.

Authors:  Y Nojima; D M Rothstein; K Sugita; S F Schlossman; C Morimoto
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Genes that regulate eosinophilic inflammation.

Authors:  D H Broide; H Hoffman; P Sriramarao
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Pathophysiological mechanisms of asthma. Application of cell and molecular biology techniques.

Authors:  K F Chung; I M Adcock
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.695

3.  3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists.

Authors:  Juswinder Singh; Herman van Vlijmen; Wen-Chemg Lee; Yusheng Liao; Ko-Chung Lin; Humayun Ateeq; Julio Cuervo; Craig Zimmerman; Charles Hammond; Michael Karpusas; Rex Palmer; Tapan Chattopadhyay; Steven P Adams
Journal:  J Comput Aided Mol Des       Date:  2002-03       Impact factor: 3.686

4.  Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma.

Authors:  Steven D Rosen; Durwin Tsay; Mark S Singer; Stefan Hemmerich; William M Abraham
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.

Authors:  Julio Cortijo; María-Jesús Sanz; Arantxa Iranzo; José Luis Montesinos; Yafa Naim Abu Nabah; José Alfón; Luis A Gómez; Manuel Merlos; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

6.  Synthesis, modeling, and biological evaluation of analogues of the semisynthetic brevetoxin antagonist beta-naphthoyl-brevetoxin.

Authors:  Sophie Michelliza; William M Abraham; Henry M Jacocks; Thomas Schuster; Daniel G Baden
Journal:  Chembiochem       Date:  2007-12-17       Impact factor: 3.164

Review 7.  The pathophysiologic role of alpha 4 integrins in vivo.

Authors:  R R Lobb; M E Hemler
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 8.  Extracellular matrix and lung inflammation.

Authors:  J Roman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 9.  Adhesion molecules in inflammatory diseases.

Authors:  R González-Amaro; F Díaz-González; F Sánchez-Madrid
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  Airway responses to aerosolized brevetoxins in an animal model of asthma.

Authors:  William M Abraham; Andrea J Bourdelais; Juan R Sabater; Ashfaq Ahmed; Troy A Lee; Irakli Serebriakov; Daniel G Baden
Journal:  Am J Respir Crit Care Med       Date:  2004-09-24       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.